vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $329.5M, roughly 1.0× Andersons, Inc.). Andersons, Inc. runs the higher net margin — 20.5% vs 13.2%, a 7.3% gap on every dollar of revenue. On growth, Andersons, Inc. posted the faster year-over-year revenue change (-2.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-77.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ANDE vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $339.0M |
| Net Profit | $67.4M | $44.7M |
| Gross Margin | 70.3% | 59.7% |
| Operating Margin | 26.6% | 19.9% |
| Net Margin | 20.5% | 13.2% |
| Revenue YoY | -2.4% | -2.7% |
| Net Profit YoY | 49.6% | 19.3% |
| EPS (diluted) | — | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $339.0M | ||
| Q3 25 | $295.8M | $327.3M | ||
| Q2 25 | $535.0M | $321.4M | ||
| Q1 25 | $370.8M | $330.6M | ||
| Q4 24 | $337.5M | $348.5M | ||
| Q3 24 | $231.9M | $345.5M | ||
| Q2 24 | $492.5M | $336.2M | ||
| Q1 24 | $341.4M | — |
| Q4 25 | $67.4M | $44.7M | ||
| Q3 25 | $20.1M | $38.7M | ||
| Q2 25 | $7.9M | $34.0M | ||
| Q1 25 | $284.0K | $58.0M | ||
| Q4 24 | $45.1M | $37.5M | ||
| Q3 24 | $27.4M | $33.8M | ||
| Q2 24 | $36.0M | $38.4M | ||
| Q1 24 | $5.6M | — |
| Q4 25 | 70.3% | 59.7% | ||
| Q3 25 | 57.8% | 59.5% | ||
| Q2 25 | 29.6% | 59.8% | ||
| Q1 25 | 41.2% | 58.4% | ||
| Q4 24 | 63.1% | 55.5% | ||
| Q3 24 | 76.4% | 54.2% | ||
| Q2 24 | 35.6% | 52.0% | ||
| Q1 24 | 37.6% | — |
| Q4 25 | 26.6% | 19.9% | ||
| Q3 25 | 8.7% | 17.9% | ||
| Q2 25 | 4.6% | 16.8% | ||
| Q1 25 | 0.9% | 21.6% | ||
| Q4 24 | 19.9% | 16.9% | ||
| Q3 24 | 26.8% | 15.0% | ||
| Q2 24 | 11.6% | 11.8% | ||
| Q1 24 | 4.1% | — |
| Q4 25 | 20.5% | 13.2% | ||
| Q3 25 | 6.8% | 11.8% | ||
| Q2 25 | 1.5% | 10.6% | ||
| Q1 25 | 0.1% | 17.5% | ||
| Q4 24 | 13.4% | 10.8% | ||
| Q3 24 | 11.8% | 9.8% | ||
| Q2 24 | 7.3% | 11.4% | ||
| Q1 24 | 1.6% | — |
| Q4 25 | — | $0.95 | ||
| Q3 25 | $0.59 | $0.81 | ||
| Q2 25 | $0.23 | $0.70 | ||
| Q1 25 | $0.01 | $1.17 | ||
| Q4 24 | $1.31 | $0.74 | ||
| Q3 24 | $0.80 | $0.66 | ||
| Q2 24 | $1.05 | $0.74 | ||
| Q1 24 | $0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $363.4M |
| Total DebtLower is stronger | $560.0M | $1.2B |
| Stockholders' EquityBook value | $1.2B | $911.5M |
| Total Assets | $3.7B | $2.5B |
| Debt / EquityLower = less leverage | 0.45× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | $561.8M | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M | ||
| Q1 24 | — | — |
| Q4 25 | $560.0M | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $911.5M | ||
| Q3 25 | $1.2B | $849.2M | ||
| Q2 25 | $1.4B | $882.3M | ||
| Q1 25 | $1.4B | $820.8M | ||
| Q4 24 | $1.4B | $906.9M | ||
| Q3 24 | $1.3B | $878.9M | ||
| Q2 24 | $1.3B | $905.4M | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $3.7B | $2.5B | ||
| Q3 25 | $3.3B | $2.4B | ||
| Q2 25 | $3.4B | $2.5B | ||
| Q1 25 | $3.8B | $2.5B | ||
| Q4 24 | $4.1B | $2.5B | ||
| Q3 24 | $3.4B | $2.5B | ||
| Q2 24 | $3.3B | $2.5B | ||
| Q1 24 | $3.3B | — |
| Q4 25 | 0.45× | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $93.6M |
| Free Cash FlowOCF − Capex | $-77.1M | $87.2M |
| FCF MarginFCF / Revenue | -23.4% | 25.7% |
| Capex IntensityCapex / Revenue | 21.5% | 1.9% |
| Cash ConversionOCF / Net Profit | -0.09× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $93.6M | ||
| Q3 25 | $233.9M | $111.3M | ||
| Q2 25 | $299.3M | $17.4M | ||
| Q1 25 | $-350.0M | $116.6M | ||
| Q4 24 | $268.8M | $43.8M | ||
| Q3 24 | $-2.1M | $48.8M | ||
| Q2 24 | $304.4M | $-27.4M | ||
| Q1 24 | $-239.6M | — |
| Q4 25 | $-77.1M | $87.2M | ||
| Q3 25 | $167.0M | $106.3M | ||
| Q2 25 | $250.5M | $13.6M | ||
| Q1 25 | $-396.6M | $100.9M | ||
| Q4 24 | $212.9M | $35.2M | ||
| Q3 24 | $-40.0M | $39.4M | ||
| Q2 24 | $275.8M | $-33.1M | ||
| Q1 24 | $-266.4M | — |
| Q4 25 | -23.4% | 25.7% | ||
| Q3 25 | 56.5% | 32.5% | ||
| Q2 25 | 46.8% | 4.2% | ||
| Q1 25 | -106.9% | 30.5% | ||
| Q4 24 | 63.1% | 10.1% | ||
| Q3 24 | -17.2% | 11.4% | ||
| Q2 24 | 56.0% | -9.8% | ||
| Q1 24 | -78.0% | — |
| Q4 25 | 21.5% | 1.9% | ||
| Q3 25 | 22.6% | 1.5% | ||
| Q2 25 | 9.1% | 1.2% | ||
| Q1 25 | 12.6% | 4.7% | ||
| Q4 24 | 16.6% | 2.5% | ||
| Q3 24 | 16.3% | 2.7% | ||
| Q2 24 | 5.8% | 1.7% | ||
| Q1 24 | 7.8% | — |
| Q4 25 | -0.09× | 2.09× | ||
| Q3 25 | 11.61× | 2.88× | ||
| Q2 25 | 38.10× | 0.51× | ||
| Q1 25 | -1232.46× | 2.01× | ||
| Q4 24 | 5.96× | 1.17× | ||
| Q3 24 | -0.08× | 1.44× | ||
| Q2 24 | 8.46× | -0.71× | ||
| Q1 24 | -42.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
